

# 1 **The complete blood count and cardiovascular disease: analyses** 2 **across six cohorts of 23,370 adults**

3 Sascha N. Goonewardena (1,2)\*, Venkatesh L. Murthy(1)#

4 <sup>1</sup> Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan,  
5 Ann Arbor, Michigan, USA

6 <sup>2</sup> Division of Cardiovascular Medicine, VA Ann Arbor Health System, Ann Arbor, Michigan, USA.

7 \*Primary contact: Sascha N. Goonewardena, MD. University of Michigan Frankel Cardiovascular  
8 Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853. Email:  
9 sngoone@med.umich.edu

10 #Contact: Venkatesh L. Murthy, MD PhD. University of Michigan Frankel Cardiovascular Center,  
11 1500 East Medical Center Drive, SPC 5873, Ann Arbor, MI 48109-5873. Email:  
12 vlmurthy@med.umich.edu

13 **Keywords:** cardiovascular disease; atherosclerosis; complete blood count; inflammation;  
14 lipoproteins; neutrophil; platelets; hemoglobin

15 **Word Count: 4,350**

16 **Abbreviations:**

17 ASCVD: atherosclerotic cardiovascular disease

18 BMP: basic metabolic panel

19 CAC: coronary artery calcification

20 CARDIA: Coronary Artery Risk Development in Young Adults

21 CBC: Complete blood count

- 1 CC: circulating cells
- 2 CM: circulating mediators
- 3 CVD: cardiovascular disease
- 4 CRIC: chronic renal insufficiency cohort
- 5 CRP: C-reactive protein
- 6 HbA1c: hemoglobin A1c
- 7 HDL: high-density lipoprotein
- 8 Hb: hemoglobin
- 9 LDL: low-density lipoprotein
- 10 MESA: Multi-Ethnic Study of Atherosclerosis
- 11 MI: myocardial infarction
- 12 NHANES: National Health and Nutrition Examination Survey
- 13 PCA: principal component analysis
- 14 PMN: neutrophil
- 15 RBC: red blood cell
- 16 WBC: white blood cell

## 1 **Abstract**

2 **Background:** The complete blood count (CBC) is one of the most commonly performed  
3 laboratory studies. Although studies have found associations between the CBC and  
4 cardiovascular disease (CVD), there is limited contemporary information regarding the  
5 relationship between the CBC and traditional risk factors and their joint association with CVD  
6 endpoints.

7 **Objective:** We sought to define the relationships between the CBC and traditional CVD risk  
8 factors and their joint association with CVD endpoints in diverse adult populations.

9 **Methods:** We first examined the relationships between the CBC variables (directly and their  
10 principal components), traditional CVD risk factors, and mortality in NHANES (n=7843). Next, we  
11 validated and extended these findings to more refined CVD endpoints in five additional cohorts  
12 (n=15,527).

13 **Results:** We first examined the variance accounted for by common laboratory studies (lipid  
14 panel, HbA1c, hs-CRP, and basic metabolic panel) by traditional risk factors in NHANES. With the  
15 exception of hemoglobin (Hb)-related components, we found that traditional risk factors  
16 accounted for less than 20% of the variance in CBC values, similar to that of lipid parameters.  
17 Additionally, in the clinically adjusted model, the CBC was more strongly associated with all-cause  
18 mortality than the lipid panel or CRP ( $p < 0.0001$ ). Next, we validated and extended these findings  
19 across five additional longitudinal cohorts with a mean follow-up of 16 years to evaluate the  
20 association of individual CBC parameters and their principal components with refined CVD  
21 endpoints. In the fully adjusted meta-analyses across the five cohorts, several CBC components  
22 including the white blood cell (WBC) count, neutrophil (PMN) count, hemoglobin (Hb) level, and  
23 an integrated immune cell score, were associated with individual CVD endpoints and a composite  
24 CV endpoint (MACE3: incident stroke, MI, and revascularization) with standardized hazard ratios  
25 of 1.13 ( $p = 0.002$ ), 1.15 ( $p = 0.0006$ ), 0.82 ( $p < 0.0001$ ), and 2.16 ( $p < 0.0001$ ) respectively.

26 **Conclusion:** This study represents the first systematic examination of the relationship between  
27 CBC features and established risk factors, as well as numerous CVD endpoints, in a diverse cohort

1 of 23,370 adults. The findings of this study underscore the potential utility of integrating CBC  
2 features into CVD risk assessment and suggest important mechanistic insights into the  
3 association between individual CBC components and the genesis of CVD.

## 1 Introduction

2 Some traditional risk factors for CVD include age, sex, and smoking.<sup>1,2</sup> Building on demographic  
3 characteristics, hemoglobin A1c (HbA1c) and creatinine (Cr) have been added to low-density  
4 lipoprotein cholesterol (LDL-C) in CVD risk estimation instruments.<sup>3,4</sup> Importantly, quantitative  
5 molecular markers such as LDL-C and C-reactive protein (CRP) have not only advanced our risk  
6 assessment but also have provided critical insights into the biological mechanisms of ASCVD and  
7 have informed the development of cardiovascular therapies.<sup>5,6</sup> Although the complete blood  
8 count (CBC) is one of the most frequently performed laboratory studies in the United States, the  
9 utility of the CBC and the individual CBC components for quantitative risk assessment of CVD is  
10 understudied.<sup>7</sup>

11 Most laboratory studies focus on measuring small molecules or proteins that serve as circulating  
12 molecular mediators (CMM) of CVD (e.g., Cr, CRP, HbA1c, and LDL-C). The CBC is the only  
13 common laboratory study that profiles circulating cells (CC) that are known to contribute to CVD  
14 through multiple mechanisms.<sup>8</sup> However, little is known about the relationship between  
15 traditional CVD risk factors and CBC components and how they together contribute to CVD risk.

16 Each of the three major aspects of the CBC (i.e., WBCs, RBCs, and platelets) has been associated  
17 with CVD (primarily in the secondary prevention setting), including atherosclerotic cardiovascular  
18 disease (ASCVD).<sup>9</sup> Specifically, oxygen-carrying capacity (RBC parameters), thrombosis (platelet  
19 parameters), and inflammation (WBC parameters) are all intimately connected to atherogenesis  
20 and specific CVD phenotypes.<sup>10</sup> With respect to oxygen-carrying capacity, several studies have  
21 found associations between RBC counts and CVD. For example, Sabatine and colleagues found  
22 that anemia was an independent predictor of MACE in acute coronary syndromes<sup>11</sup>. Platelet  
23 parameters have not only been associated with CVD risk but also are canonical cell targets to  
24 reduce CVD risk.<sup>12</sup> Inflammation is associated with the initiation, progression, and clinical  
25 manifestations of both ASCVD and CVD.<sup>13</sup> More than simply an association, several randomized  
26 control trials (RCT) of anti-inflammatory therapies have yielded promising results for ASCVD.<sup>14–16</sup>

1 Although individual CBC components have been associated with CVD, the influence of traditional  
2 risk factors on the CBC and the effect of CBC components on incident CVD endpoints across  
3 diverse, stable outpatients remain largely unknown. To further elucidate these relationships, we  
4 first examined the associations between the CBC, traditional risk factors, and mortality in  
5 NHANES (n=7843). We grouped subsets of CBC parameters representing independent axes of  
6 biological variation in NHANES using principal component (PC) analysis. We then examined the  
7 relationship between individual CBC components and PC scores on incident CVD endpoints using  
8 adjusted Cox proportional hazards models across 15,527 individuals from five longitudinal  
9 cohorts (Framingham Offspring, Framingham 3rd Gen, MESA, CRIC, and CARDIA cohorts). We  
10 demonstrated that CBC-derived parameters are powerful predictors of incident CVD in diverse  
11 adult populations, providing novel insights into the contributions of the CBC to the pathobiology  
12 and risk of CVD.

## 13 **Materials and Methods**

### 14 **NHANES**

#### 15 *Cohort description*

16 The National Health and Nutrition Examination Survey (NHANES) is a biennial weighted survey  
17 with sampling weights designed to be representative of non-institutionalized residents of the  
18 United States. We obtained data from the 2003-4, 2005-6, 2007-8, and 2009-10 cycles of NHANES  
19 and linked mortality outcomes from the National Center for Health Statistics  
20 (<https://www.cdc.gov/nchs/nhanes/index.htm>). NHANES participants provided informed  
21 consent and the overall study was approved by the NCHS Research Ethics Review Board. Because  
22 NHANES data are publicly available this analysis was exempt from local IRB review.

#### 23 *Sample selection*

24 Starting with 41,156 individual participants, we excluded individuals who were aged <20 years  
25 (N=18,983), who did not attend a fasting examination (N=11,935), and who had incomplete key

1 covariates (N=959). We further excluded participants who did not have a complete blood count  
2 (CBC) (N=374) or differential (N=29), basic metabolic profile [BMP] (N=137), C-reactive protein  
3 (CRP) (N=3), hemoglobin A1c (HbA1c) (N=24), or lipid profile (N=214). We also excluded  
4 individuals with zero or missing weight in sampling weights computed for fasting participants  
5 (N=651) and individuals where the total of all components of the differential summed to <95%  
6 or 105% (N=4).

### 7 *Laboratory measurements*

8 We evaluated commonly obtained laboratory studies including fasting lipid profile (total  
9 cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides), CBC with differential  
10 (hematocrit, hemoglobin, RBC count, WBC count, platelet count, red cell distribution width  
11 [RDW], mean corpuscular hemoglobin [MCH], mean corpuscular hemoglobin concentration  
12 [MCHC], lymphocyte percentage, neutrophil percentage, monocyte percentage, basophil  
13 percentage, eosinophil percentage, lymphocyte count, neutrophil count, monocyte count,  
14 basophil count, and eosinophil count), BMP (sodium, potassium, glucose, chloride, bicarbonate,  
15 blood urea nitrogen [BUN], creatinine, and total calcium), CRP, and HbA1c. Laboratory values  
16 were hyperbolic arcsine transformed to improve normality and scaled to zero mean and unit  
17 variance.

### 18 *Variance explained in laboratory measurements by clinical parameters*

19 We first evaluated the extent of independent information in each lab parameter by computing  
20 the variance of each transformed and scaled lab variable explained by standard clinical risk  
21 factors (*i.e.* age, sex, race, smoking, body mass index, systolic and diastolic blood pressure, use  
22 of antihypertensive medications, self-reported diabetes status) using generalized linear models  
23 accounting for fasting survey weights and type I analysis of variance.

### 24 *Outcome analyses*

25 We then related each laboratory panel (with CRP and HbA1c treated as separate panels) to all-  
26 cause mortality, cardiac mortality and cardiovascular mortality using Cox proportional hazard  
27 models, accounting for fasting survey weights. We computed unadjusted models as well as

1 models adjusted for age, sex, and race as well as models adjusted for standard clinical risk factors  
2 (age, sex, race, smoking, body mass index, systolic and diastolic blood pressure, use of  
3 antihypertensive medications, and diabetes status).

#### 4 *Principal Component Analyses*

5 Finally, we performed principal component analyses across all common laboratory panels as well  
6 as on each laboratory panel separately using varimax post-rotation, selecting the minimum  
7 number of components to explain at least 60% of total variance to group related measures within  
8 each panel and to reduce dimensionality. PCA scores were then computed for each participant  
9 and used as the key predictor in survival analysis repeated, analogous to above.

#### 10 *Repeatability of Laboratory Measures*

11 To evaluate the stability of repeated laboratory measures over time, we leverage a subsample of  
12 the 2001-2 cycle of NHANES (N=551) who were asked to return within 8 days for repeat  
13 laboratory assessments. We computed within and between subjects coefficient of variation (CV)  
14 as well as two way intra-class correlation (ICC) to assess consistency.

## 15 **Longitudinal Cohorts**

#### 16 *Cohort descriptions*

17 We then sought to validate the prognostic relevance of the CBC across multiple well-  
18 characterized longitudinal cohort studies: Coronary Artery Risk Development in Young Adults  
19 (CARDIA), Chronic Renal Insufficiency Cohort (CRIC), Framingham Heart Study (FHS) Offspring  
20 (OS) and 3rd Generation cohorts (3G), and the Multi-Ethnic Study of Atherosclerosis (MESA). Data  
21 for CARDIA, FHS OS, FHS 3G, and MESA were obtained from NHLBI BioLINCC  
22 (<https://biolincc.nhlbi.nih.gov/home/>) while data for CRIC were obtained from the NIDDK Central  
23 Repository (<https://repository.niddk.nih.gov/home/>). Participants in each study provided  
24 informed consent and each study was approved by the local IRBs at each recruitment site. This



1 secondary analysis was approved by the University of Michigan Institutional Review Board.  
2 Further details on cohorts are provided in the Supplemental methods.

### 3 *Outcomes analyses*

4 Within each cohort, we computed PCA scores for the CBC with differential variables using weights  
5 from the varimax-rotated PCA performed in NHANES. We then related the predictors (individual  
6 underlying CBC and differential variables and the PCA scores) to each outcome [incident  
7 myocardial infarction [MI], incident stroke, incident coronary revascularization, MACE3  
8 (composite of mortality, incident MI, and incident stroke), and MACE4 (composite of mortality,  
9 incident MI, incident stroke, and incident coronary revascularization), and all-cause mortality]  
10 using Cox proportional hazards regression. We performed unadjusted, adjusted for age, sex, and  
11 race, and adjusted for clinical covariates (age, sex, race, smoking, body mass index, systolic and  
12 diastolic blood pressure, use of antihypertensive medications, diabetes status, total cholesterol,  
13 HDL, LDL, and triglycerides) regression analyses. Further details of exclusions in each cohort are  
14 provided in the Supplemental methods section.

### 15 *Meta-analyses*

16 We combined standardized hazard ratios (standardized to NHANES mean and variance) using  
17 random effects meta-analyses. We performed leave one out meta-analyses to evaluate impact  
18 of individual cohorts on estimates.

### 19 *Statistical analyses*

20 All statistical analyses were performed in R 4.4.1 (R Foundation for Statistical Research, Vienna  
21 Austria). Key modules included: *metafor* (for meta-analyses), *survival* (for survival analyses),  
22 *survey* (for survey weighted analyses), *srvyr* (for survey weighted analyses), and *irr* (for  
23 intra-class correlation). Modules were obtained from the Comprehensive R Archive Network  
24 (CRAN).

## 1 Results

### 2 CBC, traditional risk factors, and all-cause mortality

3 Because traditional risk factors can influence quantitative assessments of both CM and CC, we  
4 sought first to determine the variance explained in standard laboratory studies by traditional risk  
5 factors. We leveraged data from the 2003-2010 cycles of NHANES. 7,843 subjects had complete  
6 data and were included in this first analysis. The average age was 49, and 52% were female  
7 (**Supplemental Table 1**). We used principal component analysis to partition the total variance  
8 across all laboratory values, including individual components of the CBC. Eight principal  
9 components (PC) explained 63% of the total variance across all commonly performed laboratory  
10 studies; interestingly, many of the most highly weighted features were related to the CBC,  
11 including the lymphocyte, neutrophil (PMN), and monocyte counts (**Supplemental Figure 1**).  
12 Because of the importance and strong weighting of the CBC components in relation to all  
13 common laboratory studies, we sought to define the influence of traditional CVD risk factors on  
14 the values of all individual laboratory parameters (**Figure 1A**). With respect to total cholesterol  
15 and LDL-C, less than 10% of the total variance is explained by traditional CVD risk factors. In  
16 contrast, over 30% of the variance in the values of creatinine Cr and Hb can be accounted for by  
17 traditional CVD risk factors. Conversely, most components of the CBC (except red cell  
18 parameters) are more like LDL-C (with low variance explained by traditional risk factors) than  
19 they are like CRP (with moderate or greater variance explained by traditional risk factors). Based  
20 on these observations, it was clear that the CBC itself contained a large amount of independent  
21 information relative to the other laboratory studies of CM. To build on these observations, we  
22 examined the weighted association between all-cause mortality and each of the laboratory  
23 studies using incremental chi-squared (adjusted for the traditional risk factors detailed above)  
24 (**Figure 1B**). Intriguingly, we found that the CBC and CBC components have the strongest  
25 contribution to all-cause mortality in NHANES even when compared to the lipid panel, HbA1c,  
26 CRP, and basic metabolic panel (lipid panel  $\Delta\chi^2=27.0$ ,  $p = 0.0008$ ; HbA1c  $\Delta\chi^2=6.0$ ,  $p=0.01$ ; CRP  
27  $\Delta\chi^2=64.8$ ,  $p<0.0001$ ; BMP  $\Delta\chi^2=88.8$ ,  $p<0.0001$ ; CBC  $\Delta\chi^2=215.8$ ,  $p<0.0001$ ; CBC with differential  
28  $\Delta\chi^2=258.9$ ,  $p<0.0001$ ). Because the individual components of the CBC had distinct and

1 complementary information content, we performed PCA on the CBC components to derive  
2 independent groups of CBC measures. Approximately 63% of the variance in CBC components  
3 can be captured by 4 PCs (**Figure 2A**). Interestingly, the 4 major CBC PCs could be broadly  
4 categorized as 1) PMN/lymphocytes, 2) RBC quantity, 3) other inflammatory cells, and 4) RBC  
5 properties. Additionally, the CBC and its individual components had favorable stability and intra-  
6 and intersubject variability compared with other commonly used laboratory studies,  
7 considerations important when considering the clinical utility of any quantitative biomarker  
8 (**Supplemental Figure 2**).

### 9 **CBC features are independently associated with refined CVD phenotypes in** 10 **diverse adults**

11 Building on our findings from the cross-sectional NHANES analyses, we wished to not only  
12 validate the mortality findings but also to extend them to more diverse cohorts with longitudinal  
13 follow-up leveraging more refined CVD endpoints including incident including myocardial  
14 infarction (MI), stroke, and coronary revascularization. We examined 15,527 subjects across the  
15 FHS offspring, FHS third generation, MESA, CARDIA, and CRIC cohorts. The average age in this  
16 longitudinal analysis was diverse, from young adults (CARDIA; 25 years) to older adults (FHS OS;  
17 69 years). The baseline characteristics for individuals included from each cohort are shown in  
18 **Table 1**. Over a total of 249,098 follow-up person-years there were 697 incident MI, 458 incident  
19 strokes, 234 incident coronary revascularizations, and 2,459 deaths. To understand the  
20 relationships between the CBC and these CVD endpoints, we quantified the associations between  
21 the CBC and CVD endpoints using two broad approaches. First, we quantified CVD risk across the  
22 spectrum of individual CBC components and second, we quantified CVD risk based on the four  
23 CBC PC scores derived from the cross-sectional NHANES analysis (**Supplemental data file** and  
24 **Figure 3**). In the fully adjusted model, several observations are worth noting. All CBC  
25 components except basophil, eosinophil, and platelet counts were associated with all-cause  
26 mortality. WBC, PMN, lymphocyte, and monocyte counts were associated with the CVD  
27 composite endpoint (MACE3). Additionally, even after adjusting for hs-CRP (a marker of systemic  
28 inflammation), the CBC components remained related to all-cause mortality and several CVD

1 endpoints (**Supplemental Figure 3**). Building on the PCA of CBC values in NHANES, we applied  
2 the PC dimensions to the cohorts and examined their association with more refined CVD  
3 endpoints and all-cause mortality in FHS offspring, FHS 3G, MESA, CARDIA, and CRIC cohorts  
4 (n=15,527). Numerous strong associations were evident with all of the CVD endpoints and all-  
5 cause mortality with the CBC PC dimensions (**Supplemental Figure 4**). Of note, the  
6 PMN/lymphocyte (hazard ratio 2.45 [1.42-4.24]; p=0.001) and RBC quantity (hazard ratio 1.86  
7 [1.34-2.59]; p=0.0002) PC scores were strongly associated with all-cause mortality in each cohort  
8 and when all cohorts were combined (**Figure 4**).

## 9 **Discussion**

10 In this study of 23,370 diverse adults across six cohorts, we defined the relationships between  
11 the CBC, traditional CV risk factors, CVD endpoints, and all-cause mortality. Specifically, we found  
12 that: 1) traditional CVD risk factors explain less than 10% of the variance in most CBC  
13 components; 2) CBC components were associated with all-cause mortality in all six cohorts  
14 examined; and 3) individual CBC components were strongly associated with MI,  
15 revascularization, and stroke and these effects were only modestly attenuated after adjustment  
16 for traditional risk factors and standard laboratory values including CRP. To our knowledge, this  
17 is the first study to systematically examine the association of the CBC and its components to  
18 traditional risk factors and other common laboratory studies with CVD endpoints across a large,  
19 diverse sample of adults.

20 The associations between CC and CVD were first described in a landmark case-control study in  
21 patients with MI.<sup>17</sup> Subsequently, several cohort studies have validated and built on findings  
22 from this seminal study.<sup>18,19</sup> For example, a large UK study from the CALIBER cohort  
23 demonstrated that high PMN counts and low lymphocyte counts had strong associations with  
24 myocardial infarction, peripheral arterial disease, and heart failure.<sup>20</sup> With respect to the effects  
25 of CV therapies on inflammation and WBC parameters, a recent analysis of five randomized  
26 control trials demonstrated that the NLR was associated with CV events and all-cause mortality.<sup>21</sup>  
27 Intriguingly, this analysis found that specific CV therapies, including lipid-lowering and anti-

1 inflammatory therapies, had distinct effects on the NLR, reinforcing not only that specific  
2 circulating immune cell populations are associated with CVD but also that anti-inflammatory  
3 therapeutics have distinct effects on CC populations and the immune system in general. In  
4 addition to the immune components of the CBC, RBC features have also been associated with  
5 CVD.<sup>22</sup> Sabatine and colleagues found that low values of RBC features were an independent  
6 predictor of MACE in acute coronary syndromes.<sup>11</sup> Studies have typically focused on anemia and  
7 elevated WBC counts; however, we found that even within normal ranges, WBC and RBC features  
8 are associated with CVD endpoints (**Supplemental Figure 5**). Our study builds on these prior  
9 studies, validating CBC associations with CVD even after correction for traditional ASCVD risk  
10 factors and inflammatory biomarkers.

11 The quantitative risk assessment of CVD is the cornerstone of both primary and secondary  
12 prevention. It informs patient-centered diagnostic and therapeutic approaches. The current  
13 quantitative risk approaches combine patient demographic characteristics (including age and  
14 sex), biological variables (blood pressure and smoking), and laboratory studies (lipid and diabetes  
15 parameters). Our findings add to the discourse on CVD risk assessment, suggesting that readily  
16 available laboratory information from the CBC could complement existing components of  
17 quantitative CVD risk assessments.

## 18 **Strengths and Limitations**

19 Several limitations of our study warrant consideration. First, the observational nature of our  
20 study precludes any strict determinations of causality with respect to CC pathobiology; however,  
21 we believe that our findings are hypothesis generating and can help inform future mechanistic  
22 and translational studies and underscore the importance of further characterization of CC  
23 contributions to ASCVD. Second, despite the consistency of our findings across cohorts, there is  
24 heterogeneity in the characteristics of each cohort, making comparisons imperfect. However,  
25 this heterogeneity can also be viewed as a strength, because the main conclusions are consistent  
26 across diverse cohorts, strengthens them, and makes possible more generalizations.  
27 Importantly, the triangulation from complementary approaches yielded consistent results,  
28 largely strengthening the robustness and validity of the findings.

## 1 **Conclusion**

2 In summary, these contemporary analyses of 23,370 subjects across six cohorts systematically  
3 relate the CBC to both traditional risk factors and CVD endpoints. Our findings highlight the  
4 potential of incorporating the CBC into CVD risk assessment and suggest novel mechanistic  
5 insights into the role of CBC components in the pathobiology of CVD. This study adds further  
6 evidence linking CBC components to all dimensions of CVD and furthers our understanding of  
7 how CC can be used to identify individuals at risk of CVD.

## 8 **Author Contributions**

9 SNG and VLM contributed equally, and both designed the research, analyzed the data, and wrote  
10 the paper.

## 11 **Funding and Declaration of Interests**

12 Dr. Goonewardena is supported by VA MERIT grant 1I01CX002560, NIH/NHLBI grant  
13 R01HL150392, and the Taubman Medical Research Institute (Wolfe Scholarship). Dr. Murthy  
14 owns stock or stock options in General Electric, Amgen, Cardinal Health, Ionetix, Boston Scientific,  
15 Merck, Eli Lilly, Johnson and Johnson, Viatrix, and Pfizer. He has received research grants and  
16 consulting fees from Siemens Medical Imaging. He has served on medical advisory boards for  
17 Ionetix. He is a consultant for INVIA Medical Imaging Solutions. Dr. Murthy is supported in part  
18 by grants from the National Institute of Diabetes, Digestive, and Kidney Diseases (U01DK123013-  
19 03); National Institute on Aging (R01 AG059729); National Heart, Lung and Blood Institute (R01  
20 HL136685); American Heart Association Strategically Focused Research Network grant in  
21 Cardiometabolic Disease; and the Melvyn Rubenfire Professorship in Preventive Cardiology.

## 22 **Data and Code Availability**

23 Data for NHANES are freely available from the National Center for Health Statistics

1 Data for CARDIA, FHS OS, FHS 3G and MESA were obtained from NHLBI BioLINCC and can be  
2 obtained by qualified investigators from NHLBI with an approved research proposal, data use  
3 agreement and IRB approval.

4 Data for CRIC were obtained from the NIDDK Central Repository and can be obtained by qualified  
5 investigators from NHLBI with an approved research proposal, data use agreement and IRB  
6 approval.

7 No new software algorithms or tools were developed for this project.

## 8 **Acknowledgements**

9 Although not directly involved in the conduct of this study, we thank the research volunteers and  
10 staff of the underlying studies for their contributions and commitment to research.

## 11 **References**

- 12 1. Artola Arita V, Beigrezaei S, Franco OH. Risk factors for cardiovascular disease: the known  
13 unknown. *European Journal of Preventive Cardiology* 2024;31:e106–e107.  
14 doi:10.1093/eurjpc/zwad392.
- 15 2. Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, et al. Ten things to know  
16 about ten cardiovascular disease risk factors. *American Journal of Preventive Cardiology*  
17 2021;5:100149. doi:10.1016/j.ajpc.2021.100149.
- 18 3. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013  
19 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American  
20 College of Cardiology/American Heart Association Task Force on Practice Guidelines.  
21 *Circulation* 2014;129. doi:10.1161/01.cir.0000437741.48606.98.
- 22 4. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and  
23 Validation of the American Heart Association’s PREVENT Equations. *Circulation*  
24 2024;149:430–449. doi:10.1161/CIRCULATIONAHA.123.067626.
- 25 5. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin Therapy, LDL  
26 Cholesterol, C-Reactive Protein, and Coronary Artery Disease. *N Engl J Med* 2005;352:29–  
27 38. doi:10.1056/NEJMoa042000.
- 28 6. Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee I-M, Buring JE. Inflammation, Cholesterol,  
29 Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women. *N Engl J Med*  
30 2024;NEJMoa2405182. doi:10.1056/NEJMoa2405182.
- 31 7. Medicare Part B Spending on Clinical Diagnostic Laboratory Tests in 2022 n.d.
- 32 8. Mallat Z, Tedgui A. Century of Milestones and Breakthroughs Related to the Immune



- 1 Mechanisms of Atherosclerosis. *ATVB* 2024;44:1002–1006.
- 2 doi:10.1161/ATVBAHA.124.319397.
- 3 9. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, et al. Which White Blood
- 4 Cell Subtypes Predict Increased Cardiovascular Risk? *Journal of the American College of*
- 5 *Cardiology* 2005;45:1638–1643. doi:10.1016/j.jacc.2005.02.054.
- 6 10. Seo I-H, Lee Y-J. Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and
- 7 Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review. *Biomedicines*
- 8 2022;10:2697. doi:10.3390/biomedicines10112697.
- 9 11. Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH, et al.
- 10 Association of Hemoglobin Levels With Clinical Outcomes in Acute Coronary Syndromes.
- 11 *Circulation* 2005;111:2042–2049. doi:10.1161/01.CIR.0000162477.70955.5F.
- 12 12. Tsai M-T, Chen Y-T, Lin C-H, Huang T-P, Tarng D-C. U-shaped mortality curve associated with
- 13 platelet count among older people: a community-based cohort study. *Blood*
- 14 2015;126:1633–1635. doi:10.1182/blood-2015-06-654764.
- 15 13. Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, et al. Targeting
- 16 cardiovascular inflammation: next steps in clinical translation. *European Heart Journal*
- 17 2021;42:113–131. doi:10.1093/eurheartj/ehaa099.
- 18 14. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al.
- 19 Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. *N Engl J Med*
- 20 2017;377:1119–1131. doi:10.1056/NEJMoa1707914.
- 21 15. Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of
- 22 Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med* 2019;381:2497–2505.
- 23 doi:10.1056/NEJMoa1912388.
- 24 16. Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al. IL-6
- 25 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind,
- 26 randomised, placebo-controlled, phase 2 trial. *The Lancet* 2021;397:2060–2069.
- 27 doi:10.1016/S0140-6736(21)00520-1.
- 28 17. Leukocyte Count and Myocardial Infarction: Correction. *N Engl J Med* 1974;291:1361–1361.
- 29 doi:10.1056/NEJM197412192912517.
- 30 18. Horne BD, May HT, Muhlestein JB, Ronnow BS, Lappé DL, Renlund DG, et al. Exceptional
- 31 Mortality Prediction by Risk Scores from Common Laboratory Tests. *The American Journal*
- 32 *of Medicine* 2009;122:550–558. doi:10.1016/j.amjmed.2008.10.043.
- 33 19. Wheeler J. Associations between differential leucocyte count and incident coronary heart
- 34 disease: 1764 incident cases from seven prospective studies of 30 374 individuals. *European*
- 35 *Heart Journal* 2004;25:1287–1292. doi:10.1016/j.ehj.2004.05.002.
- 36 20. Shah AD, Denaxas S, Nicholas O, Hingorani AD, Hemingway H. Neutrophil Counts and Initial
- 37 Presentation of 12 Cardiovascular Diseases. *Journal of the American College of Cardiology*
- 38 2017;69:1160–1169. doi:10.1016/j.jacc.2016.12.022.
- 39 21. Adamstein NH, MacFadyen JG, Rose LM, Glynn RJ, Dey AK, Libby P, et al. The neutrophil–
- 40 lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary
- 41 randomized trials. *European Heart Journal* 2021;42:896–903.
- 42 doi:10.1093/eurheartj/ehaa1034.
- 43 22. Lee WJ, Choi S, Park SM, Lee G, Chang J, Oh YH, et al. Association of hemoglobin variability
- 44 with the risk of cardiovascular disease: a nationally representative retrospective cohort



- 1 study from South Korea. Sci Rep 2023;13:2148. doi:10.1038/s41598-023-28029-w.
- 2
- 3

# 1 Tables

## 2 Table 1. Participant characteristics of longitudinal cohorts

3


Characteristic	FHS OS N = 1,816 <sup>1</sup>	FHS 3G N = 2,629 <sup>1</sup>	MESA N=2,598 <sup>1</sup>	CARDIA N = 4,768 <sup>1</sup>	CRIC N = 3,716 <sup>1</sup>
Age	69 (64, 75)	48 (41, 54)	68 (61, 76)	25.0 (22.0, 28.0)	59 (52, 66)
Female Sex	1,062 (58%)	1,379 (52%)	1,406 (54%)	2,607 (55%)	1,669 (45%)
Race					
White	1,731 (95%)	2,358 (90%)	1,118 (43%)	2,329 (49%)	1,736 (47%)
Non-White	15 (0.8%)	271 (10%)			
Black			724 (28%)	2,439 (51%)	1,489 (40%)
Chinese-American			24 (0.9%)		
Hispanic			732 (28%)		
American Indian/Alaska native					15 (0.4%)
Asian					105 (2.8%)
More than one race					78 (2.1%)
Native Hawaiian/Pacific Islands					6 (0.2%)
Unknown	70 (3.9%)				287 (7.7%)
Smoking					
current	111 (6.1%)	243 (9.2%)	211 (8.1%)	1,461 (31%)	488 (13%)
former	984 (54%)	819 (31%)	1095 (42%)	638 (13%)	1,542 (41%)
never	721 (40%)	1,567 (60%)	1,275 (49%)	2,669 (56%)	1,686 (45%)
Body Mass Index	27.7 (24.7, 31.1)	27.1 (24.1, 31.1)	28.5 (25.2, 32.4)	23.5 (21.1, 26.4)	31 (27, 36)
Total Cholesterol	187 (163, 210)	184 (163, 207)	181 (157, 206)	173 (153, 197)	178 (152, 208)
HDL Cholesterol	61 (49, 75)	57 (47, 71)	53 (44, 64)	52 (44, 61)	45 (37, 54)
LDL Cholesterol	99 (82, 121)	102 (83, 123)	104 (83, 126)	106 (87, 127)	98 (78, 123)
Triglycerides	99 (75, 137)	94 (68, 134)	93 (70, 130)	62 (45, 84)	128 (89, 185)

Systolic Blood Pressure	126 (115, 137)	116 (107, 126)	120 (110, 136)	110 (103, 117)	125 (113, 141)
Diastolic Blood Pressure	72 (66, 79)	75 (68, 81)	68 (61, 75)	68 (62, 75)	71 (62, 80)
BP Medication Use	949 (52%)	488 (19%)	1,433 (55%)	107 (2.2%)	3,608 (97%)
Diabetes					
Diabetic	246 (14%)	128 (4.9%)	511 (20%)	40 (0.8%)	1,800 (48%)
Non-Diabetic	1,570 (86%)	2,501 (95%)	2,087 (80%)		1,916 (52%)
High Sensitivity C-Reactive Protein	1.54 (0.77, 3.21)	1.27 (0.61, 2.95)	2.1 (0.9, 4.4)		3 (1, 6)
Hematocrit	40.0 (37.7, 42.5)	40.8 (38.4, 43.7)	40.0 (37.5, 42.7)	42.0 (39.0, 45.5)	37.4 (34.2, 40.9)
Hemoglobin	13.70 (12.90, 14.50)	14.00 (13.10, 15.00)	13.40 (12.40, 14.40)	14.20 (13.20, 15.30)	12.55 (11.40, 13.80)
RBC Count	4.33 (4.07, 4.63)	4.51 (4.23, 4.84)	4.48 (4.15, 4.79)	4.78 (4.41, 5.17)	4.26 (3.86, 4.66)
WBC Count	5.75 (4.80, 6.90)	5.80 (4.90, 6.80)	5.80 (4.80, 6.90)	5.80 (4.80, 7.10)	6.30 (5.20, 7.70)
Mean Corpuscular Hemoglobin	31.60 (30.50, 32.50)	31.10 (30.10, 32.00)	30.20 (28.90, 31.40)	29.93 (28.66, 31.07)	30.00 (28.40, 31.00)
Mean Corpuscular Hemoglobin Concentration	34.20 (33.60, 34.70)	34.20 (33.70, 34.60)	33.40 (32.80, 34.10)	33.76 (33.18, 34.30)	33.70 (33.00, 34.20)
Mean Corpuscular Volume	92.5 (89.8, 95.2)	90.8 (88.2, 93.5)	90.0 (87.0, 93.0)		88.8 (85.0, 92.0)
Red Cell Distribution Width	13.00 (12.60, 13.50)	12.70 (12.40, 13.20)	13.90 (13.40, 14.60)		
Platelet Count	229 (197, 268)	241 (207, 278)	224 (187, 266)	267 (227, 313)	237 (195, 284)
Platelet Volume	8.80 (8.20, 9.40)	8.40 (7.90, 9.00)			
Lymphocytes (%)	26 (21, 31)	28 (24, 33)	30 (24, 36)	37 (30, 43)	27 (21, 33)
Neutrophils (%)	61 (55, 66)	59 (54, 64)	59 (53, 65)	53 (46, 60)	62 (55, 68)
Monocytes (%)	8.80 (7.50, 10.20)	8.40 (7.20, 9.80)	8.00 (6.00, 9.00)	5.00 (4.00, 7.00)	7.30 (6.00, 8.94)
Basophils (%)	0.60 (0.40, 0.80)	0.80 (0.60, 1.00)	1.00 (0.00, 1.00)	0.00 (0.00, 1.00)	0.40 (0.00, 0.90)
Eosinophils (%)	2.90 (2.00, 4.20)	2.60 (1.80, 3.90)	2.00 (1.00, 4.00)	2.00 (1.00, 3.00)	2.78 (1.72, 4.12)
Lymphocyte Count	1.50 (1.20, 1.80)	1.60 (1.30, 1.90)	1.70 (1.35, 2.10)	2.10 (1.73, 2.54)	1.65 (1.30, 2.09)

Neutrophil Count	3.50 (2.80, 4.30)	3.40 (2.70, 4.20)	3.40 (2.70, 4.30)	3.02 (2.30, 4.02)	3.83 (2.95, 4.96)
Monocyte Count	0.50 (0.40, 0.60)	0.50 (0.40, 0.60)	0.40 (0.31, 0.57)	0.30 (0.20, 0.41)	0.46 (0.36, 0.60)
Basophil Count	0.00 (0.00, 0.00)	0.00 (0.00, 0.10)	0.00 (0.00, 0.05)	0.00 (0.00, 0.06)	0.03 (0.00, 0.05)
Eosinophil Count	0.20 (0.10, 0.30)	0.20 (0.10, 0.20)	0.10 (0.10, 0.20)	0.12 (0.06, 0.20)	0.18 (0.10, 0.27)
Neutrophil:Lymphocyte Ratio	2.35 (1.77, 3.10)	2.10 (1.65, 2.64)	1.97 (1.46, 2.69)	1.45 (1.07, 1.97)	2.32 (1.73, 3.18)
Incident MACE3	267 (15%)	78 (3.0%)	214 (8.2%)	620 (13%)	1,793 (48%)
Incident MACE4	285 (16%)	99 (3.8%)	239 (9.2%)	651 (14%)	
Incident MI	33 (1.8%)	24 (0.9%)	41 (1.6%)	104 (2.2%)	495 (13%)
Incident Stroke	43 (2.4%)	14 (0.5%)	52 (2.0%)	109 (2.3%)	240 (6.5%)
Incident Coronary Revascularization	42 (2.3%)	40 (1.5%)	46 (1.8%)	106 (2.2%)	
All Cause Mortality	218 (12%)	43 (1.6%)	148 (5.7%)	470 (9.9%)	1,580 (43%)

1 1 Median (Q1, Q3); n (%)


# 1 Figures



2

## 3 **Figure 1. The variance explained of common laboratory studies by traditional risk** 4 **factors and information content for all-cause mortality.**

5 A) We leveraged data from the 2003-2010 cycles of NHANES to assess the variance explained of  
 6 common laboratory measures by traditional risk factors using 6,162 subjects with complete data  
 7 and fasting status. Type I analysis of variance accounting for survey weights was performed to  
 8 estimate percent variance explained after hyperbolic arcsine transformation. These results  
 9 illustrate that values from the CBC had comparable independent information content beyond  
 10 traditional risk factors and comparable to that of lipid and basic metabolic panels. B) Using  
 11 incremental chi-squared, we examined the survey-weighted association between common  
 12 laboratory panels and all-cause mortality. Adjustments were made for age, sex, race, smoking,  
 13 BMI, blood pressure, use of antihypertensive medications, and self-reported diabetes. Higher  $\chi^2$   
 14 indicates greater information content.




1

2 **Figure 2. Dimension reduction of the CBC and information content for all-cause**  
 3 **mortality.**


4 A) Principal component analysis (PCA) of the CBC with differential demonstrated that four  
 5 components explain 62.9% of the total variance in the CBC with differential study. PCA was  
 6 performed with varimax post-rotation and accounted for survey sampling weights for the fasting  
 7 subpopulation in NHANES. The first component (explaining 20.5% of the total variance) was  
 8 positively loaded on total WBC count, neutrophils, and NLR and negatively loaded on  
 9 lymphocytes. The second component (explaining for 14.3% of the total variance) was loaded on  
 10 red blood cell quantity measures, negatively loaded on RBC count, hematocrit, and hemoglobin.  
 11 The third component (explaining 13.7% of total variance) was negatively loaded with multiple  
 12 inflammatory cell parameters including total WBC count, lymphocytes, and eosinophils. Finally,

1 the fourth component (explaining 14.1% of total variance) was loaded on red blood cell  
 2 characteristics with positive loadings for MCH, MCHC, and MCV and negative loading for RDW.  
 3 B) Analogously to Figure 2, we computed incremental  $\chi^2$  for Cox proportional hazards models for  
 4 all-cause mortality adding rotated principal components of common laboratory panels to clinical  
 5 variables (*i.e.* age, sex, race, smoking, body mass index, systolic and diastolic blood pressure, use  
 6 of antihypertensive medications, self-reported diabetes status). Higher  $\chi^2$  indicates greater  
 7 information content. Models accounted for survey sampling weights for the fasting  
 8 subpopulation in NHANES.



9  
 10 **Figure 3. CBC components are associated with refined CV endpoints across five**  
 11 **diverse, longitudinal cohorts.**

12 Heatmap of standardized  $\beta$ -coefficients from Cox proportional hazards models relating CBC  
 13 components to CV endpoints. Values of standardized  $\beta$ -coefficients directionality (color),  
 14 magnitude (color gradient), and statistical significance (color of circle) are depicted. All models  
 15 are fully adjusted for age, sex, race, smoking, body mass index, systolic and diastolic blood  
 16 pressure, use of antihypertensive medications, diabetes status, total cholesterol, HDL, LDL, and  
 17 triglycerides.



1

2 **Figure 4. Key CBC-derived scores for all-cause mortality and MACE3 across five**  
3 **longitudinal cohorts.**

4 Forest plots of standardized  $\beta$ -coefficients of key CBC-derived scores for all-cause mortality and  
5 MACE3. Tables on the left indicate the number of total subjects and events in each cohort.  
6 Hazard ratios (circles) and their 95% confidence intervals (bars) are indicated in different colors  
7 for individual cohort estimates (coral), summary meta-analysis (blue), and leave one cohort  
8 analysis sensitivity analyses (green). Cox models in each cohort were adjusted for age, sex, race,  
9 smoking, body mass index, systolic and diastolic blood pressure, use of antihypertensive  
10 medications, diabetes status, total cholesterol, HDL, LDL, and triglycerides.